News about Drug Discovery & Development

Strides Receives Tentative USFDA Approval for Dolutegravir / Lamivudine / Tenofovir Disproxil Fumurate tablets

Strides Receives Tentative USFDA Approval for Dolutegravir / Lamivudine / Tenofovir Disproxil Fumurate tablets

Approval of this product under the PEPFAR program completes Strides' qualification to all major markets and donor programs including Global Fund and South Africa.

Drug Discovery & Development | 19/09/2023 | By Manvi 529

Zydus Gets Final Approval from USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day

Zydus Gets Final Approval from USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day

Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day.

Drug Discovery & Development | 19/09/2023 | By Manvi 759

Strides Pharma Gets USFDA Tentative Nod for Generic HIV Treatment Drug

Strides Pharma Gets USFDA Tentative Nod for Generic HIV Treatment Drug

Strides Pharma Science Ltd said its wholly-owned subsidiary Strides Pharma Global Pte Ltd, Singapore, has received tentative approval from the US health regulator for generic Dolutegravir tablets used in the treatment of HIV.

Drug Discovery & Development | 15/09/2023 | By Manvi 615

Sun Pharma and Pharmazz Enter into Licensing Agreement for Introducing Tyvalzi in India

Sun Pharma and Pharmazz Enter into Licensing Agreement for Introducing Tyvalzi in India

As per agreement terms, Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi™ (Sovateltide). Pharmazz will be entitled to upfront and milestone payments, including royalties.

Drug Discovery & Development | 15/09/2023 | By Manvi 1572

Gufic Biosciences Ltd Receives TGA Australia and ANVISA Brazil Approval for Parecoxib 40mg Injection

Gufic Biosciences Ltd Receives TGA Australia and ANVISA Brazil Approval for Parecoxib 40mg Injection

Gufic has been persistently committed to saving and improving lives of patients across the globe with its continuous efforts through the international regulatory agencies to bring novel molecules for the mankind.

Drug Discovery & Development | 12/09/2023 | By Manvi 970

Lupin Collaborates with Mark Cuban Cost Plus Drug Company and COPD Foundation to Expand Access to Medication for COPD Patients

Lupin Collaborates with Mark Cuban Cost Plus Drug Company and COPD Foundation to Expand Access to Medication for COPD Patients

Lupin's Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, is currently the only generic product available that is therapeutically equivalent to Spiriva® HandiHaler® (Tiotropium Bromide Inhalation Powder), 18 mcg/capsule by Boehringer Ingelheim Pharmaceuticals, Inc.

Drug Discovery & Development | 08/09/2023 | By Manvi 492

DCGI Issues Alert Against Antacid Digene Gel, Abbott Initiates Voluntary Recall

DCGI Issues Alert Against Antacid Digene Gel, Abbott Initiates Voluntary Recall

The company announced that it had withdrawn all its batches that were being manufactured at its Goa facility following a complaint from a customer that the liquid in the bottle had turned white, tasted bitter, and had a pungent smell when they bought it

Drug Discovery & Development | 07/09/2023 | By Manvi 1788

Serum Institute of India to Launch Malaria Vaccine Soon

Serum Institute of India to Launch Malaria Vaccine Soon

This was announced by Managing Director Cyrus Poonawala during a press conference.

Drug Discovery & Development | 01/09/2023 | By Manvi 810

Lonza and Vertex to Establish Manufacturing Facility for Cell Therapy in Portsmouth

Lonza and Vertex to Establish Manufacturing Facility for Cell Therapy in Portsmouth

The facility marks a milestone in the strategic collaboration between the two firms.

Drug Discovery & Development | 01/09/2023 | By Manvi 1138

WuXi Biologics, Boostimmune Ink MOU for Exclusive R&D Services

WuXi Biologics, Boostimmune Ink MOU for Exclusive R&D Services

WuXi Biologics, Boostimmune Ink MOU for Exclusive R&D Services<br />

Drug Discovery & Development | 24/08/2023 | By Sudeep Soparkar 866

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members